9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe

AI Summary

Nine pharmaceutical leaders have raised concerns about the decline of biotech innovation in Europe compared to the U.S. and China. They advocate for accelerated clinical trials, stronger intellectual property protections, and greater fiscal flexibility to revitalize Europe's pharma sector.

Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”